Blake Glen M, Fogelman Ignac
King's College London School of Medicine, London, UK.
J Clin Densitom. 2007 Jan-Mar;10(1):102-10. doi: 10.1016/j.jocd.2006.11.001. Epub 2006 Dec 27.
Dual energy X-ray absorptiometry (DXA) measurements of spine and hip bone mineral density (BMD) (referred to here as central DXA) have an important role as a clinical tool for the evaluation of individuals at risk of osteoporosis, and in helping clinicians give advice to patients about the appropriate use of antifracture treatment. Compared with alternative bone densitometry techniques such quantitative computed tomography (QCT), peripheral DXA (pDXA) and quantitative ultrasound (QUS), central DXA has a number of significant advantages that include a consensus that BMD results can be interpreted using the World Health Organization (WHO) T-score definition of osteoporosis, a proven ability to predict fracture risk, and proven effectiveness at targeting antifracture treatments. This review article discusses the evidence for these and other advantages of central DXA, including its role in the new WHO algorithm for treating patients on the basis of individual fracture risk.
采用双能X线吸收法（DXA）测量脊柱和髋部骨密度（BMD）（以下简称中央DXA），作为一种临床工具，在评估骨质疏松症风险个体以及帮助临床医生就抗骨折治疗的合理使用向患者提供建议方面发挥着重要作用。与其他骨密度测量技术如定量计算机断层扫描（QCT）、外周DXA（pDXA）和定量超声（QUS）相比，中央DXA具有许多显著优势，包括人们达成共识，即骨密度结果可根据世界卫生组织（WHO）骨质疏松症T值定义进行解读，具备预测骨折风险的经证实能力，以及在靶向抗骨折治疗方面的经证实有效性。这篇综述文章讨论了中央DXA的这些及其他优势的证据，包括其在世界卫生组织基于个体骨折风险治疗患者的新算法中的作用。
